Steve Georas1,2,3, Nicole Ransom1, Sara Hillman1, Sophia Eliseeva1, Janelle Veazey2, Timothy Smyth3, Kim Le4, Jon Meddings4. 1. Department of Medicine, University of Rochester Medical Center , Rochester, NY , USA. 2. Department of Microbiology & Immunology, University of Rochester Medical Center , Rochester, NY , USA. 3. Department of Environmental Health Sciences, University of Rochester Medical Center , Rochester, NY , USA. 4. Cumming School of Medicine, University of Calgary , Calgary , Alberta.
Abstract
Objective: Airway epithelial barrier dysfunction is emerging as an important feature of asthma pathogenesis, but this is difficult to measure in individual subjects. We aimed to develop a noninvasive way to measure airway permeability in asthma. Methods: Healthy controls and subjects with mild asthma inhaled dry powder mannitol in a dose-escalating manner on two separate occasions, stopping at 155 mg or 315 mg. Serum mannitol levels were measured at baseline and then 30, 90, and 150 min after mannitol inhalation. Mannitol absorption was compared with measurements of airflow obstruction (FEV1) and airway inflammation (FeNO). Results: Serum mannitol levels increased in a time- and dose-dependent manner in both healthy control and subjects with asthma. There were no significant differences in mannitol absorption when comparing healthy controls and subjects with asthma. Mannitol absorption did not correlate with markers of airway obstruction or inflammation. Conclusions: Measuring serum concentrations of mannitol after inhalation challenge can potentially provide insights into airway barrier function in asthma.
Objective: Airway epithelial barrier dysfunction is emerging as an important feature of asthma pathogenesis, but this is difficult to measure in individual subjects. We aimed to develop a noninvasive way to measure airway permeability in asthma. Methods: Healthy controls and subjects with mild asthma inhaled dry powder mannitol in a dose-escalating manner on two separate occasions, stopping at 155 mg or 315 mg. Serum mannitol levels were measured at baseline and then 30, 90, and 150 min after mannitol inhalation. Mannitol absorption was compared with measurements of airflow obstruction (FEV1) and airway inflammation (FeNO). Results: Serum mannitol levels increased in a time- and dose-dependent manner in both healthy control and subjects with asthma. There were no significant differences in mannitol absorption when comparing healthy controls and subjects with asthma. Mannitol absorption did not correlate with markers of airway obstruction or inflammation. Conclusions: Measuring serum concentrations of mannitol after inhalation challenge can potentially provide insights into airway barrier function in asthma.
Authors: Robert P Schleimer; Atsushi Kato; Robert Kern; Douglas Kuperman; Pedro C Avila Journal: J Allergy Clin Immunol Date: 2007-10-18 Impact factor: 10.793
Authors: N P Breslin; C Nash; R J Hilsden; N B Hershfield; L M Price; J B Meddings; L R Sutherland Journal: Am J Gastroenterol Date: 2001-10 Impact factor: 10.864
Authors: Umadevi Sajjan; Qiong Wang; Ying Zhao; Dieter C Gruenert; Marc B Hershenson Journal: Am J Respir Crit Care Med Date: 2008-09-11 Impact factor: 21.405
Authors: Fariba Rezaee; Samantha A DeSando; Andrei I Ivanov; Timothy J Chapman; Sara A Knowlden; Lisa A Beck; Steve N Georas Journal: J Virol Date: 2013-08-07 Impact factor: 5.103
Authors: F Broeckaert; K Arsalane; C Hermans; E Bergamaschi; A Brustolin; A Mutti; A Bernard Journal: Environ Health Perspect Date: 2000-06 Impact factor: 9.031